All drugs
Olverembatinib (HQP1351)
Stage Phase 3
Sponsor Ascentage Pharma
Route oral tablet
Modality small molecule
Class multi-kinase TKI
Mechanism kinase inhibitor; proposed p38/CD36 mechanism in SDH-deficient GIST per sponsor abstract
Target SDH-deficient GIST (no kinase driver)
Target ABL1 (approved use elsewhere) (TEC-0105)
Sources
publication, as of 2026-11-07
https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11539
a total of 32 pts, including 26 pts with IHC-confirmed SDH-deficient GIST, had received olverembatinib ... Six (23.1%) pts experienced PR as best response, and the median PFS was 25.7 (range 12.9-NR) months.
J Clin Oncol 44(16_suppl) abstract 11539 (ASCO 2026), NCT03594422; congress abstract, preliminary
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03594422
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06640361
A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
Studies
Registry NCT03594422
Phase Phase 1
Status Recruiting
Enrollment 100
Start 2018-07-11
Primary completion 2027-12
Study completion 2028-12
Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.
Olverembatinib 30 to 50 mg every other day
Dose 30 to 50 mg
Regimen every other day
Population SDH-deficient GIST (n = 26)
Estimand Single arm
partial response as best response: 23.1%, cutoff 11.13.2025
median progression-free survival: 25.7 months, cutoff 11.13.2025
Registry NCT06640361
Phase Phase 3
Status Recruiting
Enrollment 40
Start 2024-11-11
Primary completion 2027-03-31
Study completion 2029-06-30
Catalyst Primary completion. 03.31.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.